353 related articles for article (PubMed ID: 29221488)
1. Divergent susceptibilities to AAV-SaCas9-gRNA vector-mediated genome-editing in a single-cell-derived cell population.
Morsy SG; Tonne JM; Zhu Y; Lu B; Budzik K; Krempski JW; Ali SA; El-Feky MA; Ikeda Y
BMC Res Notes; 2017 Dec; 10(1):720. PubMed ID: 29221488
[TBL] [Abstract][Full Text] [Related]
2. In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models.
Yin C; Zhang T; Qu X; Zhang Y; Putatunda R; Xiao X; Li F; Xiao W; Zhao H; Dai S; Qin X; Mo X; Young WB; Khalili K; Hu W
Mol Ther; 2017 May; 25(5):1168-1186. PubMed ID: 28366764
[TBL] [Abstract][Full Text] [Related]
3. Promoter Orientation within an AAV-CRISPR Vector Affects Cas9 Expression and Gene Editing Efficiency.
Fry LE; Peddle CF; Stevanovic M; Barnard AR; McClements ME; MacLaren RE
CRISPR J; 2020 Aug; 3(4):276-283. PubMed ID: 32833533
[TBL] [Abstract][Full Text] [Related]
4. Delivering SaCas9 mRNA by lentivirus-like bionanoparticles for transient expression and efficient genome editing.
Lu B; Javidi-Parsijani P; Makani V; Mehraein-Ghomi F; Sarhan WM; Sun D; Yoo KW; Atala ZP; Lyu P; Atala A
Nucleic Acids Res; 2019 May; 47(8):e44. PubMed ID: 30759231
[TBL] [Abstract][Full Text] [Related]
5. AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9.
Li A; Tanner MR; Lee CM; Hurley AE; De Giorgi M; Jarrett KE; Davis TH; Doerfler AM; Bao G; Beeton C; Lagor WR
Mol Ther; 2020 Jun; 28(6):1432-1441. PubMed ID: 32348718
[TBL] [Abstract][Full Text] [Related]
6. Construction of an Inducible CRISPR/Cas9 System for CXCR4 Gene and Demonstration of its Effects on MKN-45 Cells.
Peng Y; Yang T; Tang X; Chen F; Wang S
Cell Biochem Biophys; 2020 Mar; 78(1):23-30. PubMed ID: 31875277
[TBL] [Abstract][Full Text] [Related]
7. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
8. In Vivo Ryr2 Editing Corrects Catecholaminergic Polymorphic Ventricular Tachycardia.
Pan X; Philippen L; Lahiri SK; Lee C; Park SH; Word TA; Li N; Jarrett KE; Gupta R; Reynolds JO; Lin J; Bao G; Lagor WR; Wehrens XHT
Circ Res; 2018 Sep; 123(8):953-963. PubMed ID: 30355031
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus.
Liu Y; Zhao M; Gong M; Xu Y; Xie C; Deng H; Li X; Wu H; Wang Z
Antiviral Res; 2018 Apr; 152():58-67. PubMed ID: 29458131
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice.
El Refaey M; Xu L; Gao Y; Canan BD; Adesanya TMA; Warner SC; Akagi K; Symer DE; Mohler PJ; Ma J; Janssen PML; Han R
Circ Res; 2017 Sep; 121(8):923-929. PubMed ID: 28790199
[TBL] [Abstract][Full Text] [Related]
11. Rational Design of Mini-Cas9 for Transcriptional Activation.
Ma D; Peng S; Huang W; Cai Z; Xie Z
ACS Synth Biol; 2018 Apr; 7(4):978-985. PubMed ID: 29562138
[TBL] [Abstract][Full Text] [Related]
12. Genome scale screening identification of SaCas9/gRNAs for targeting HIV-1 provirus and suppression of HIV-1 infection.
Wang Q; Liu S; Liu Z; Ke Z; Li C; Yu X; Chen S; Guo D
Virus Res; 2018 May; 250():21-30. PubMed ID: 29625148
[TBL] [Abstract][Full Text] [Related]
13. Genome modification of CXCR4 by Staphylococcus aureus Cas9 renders cells resistance to HIV-1 infection.
Wang Q; Chen S; Xiao Q; Liu Z; Liu S; Hou P; Zhou L; Hou W; Ho W; Li C; Wu L; Guo D
Retrovirology; 2017 Nov; 14(1):51. PubMed ID: 29141633
[TBL] [Abstract][Full Text] [Related]
14. Highly specific targeted mutagenesis in plants using Staphylococcus aureus Cas9.
Kaya H; Mikami M; Endo A; Endo M; Toki S
Sci Rep; 2016 May; 6():26871. PubMed ID: 27226350
[TBL] [Abstract][Full Text] [Related]
15. The gRNA Vector Level Determines the Outcome of Systemic AAV CRISPR Therapy for Duchenne Muscular Dystrophy.
Wasala NB; Million ED; Watkins TB; Wasala LP; Han J; Yue Y; Lu B; Chen SJ; Hakim CH; Duan D
Hum Gene Ther; 2022 May; 33(9-10):518-528. PubMed ID: 35350865
[TBL] [Abstract][Full Text] [Related]
16. Rationally engineered
Tan Y; Chu AHY; Bao S; Hoang DA; Kebede FT; Xiong W; Ji M; Shi J; Zheng Z
Proc Natl Acad Sci U S A; 2019 Oct; 116(42):20969-20976. PubMed ID: 31570596
[TBL] [Abstract][Full Text] [Related]
17. Two high-fidelity variants: efSaCas9 and SaCas9-HF, which one is better?
Lv J; Xi H; Lv X; Zhou Y; Wang J; Chen H; Yan T; Jin J; Zhao J; Gu F; Song Z
Gene Ther; 2022 Aug; 29(7-8):458-463. PubMed ID: 35095097
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9 as an antiviral against Orthopoxviruses using an AAV vector.
Siegrist CM; Kinahan SM; Settecerri T; Greene AC; Santarpia JL
Sci Rep; 2020 Nov; 10(1):19307. PubMed ID: 33168908
[TBL] [Abstract][Full Text] [Related]
19. Prevention of acquired sensorineural hearing loss in mice by in vivo Htra2 gene editing.
Gu X; Wang D; Xu Z; Wang J; Guo L; Chai R; Li G; Shu Y; Li H
Genome Biol; 2021 Mar; 22(1):86. PubMed ID: 33752742
[TBL] [Abstract][Full Text] [Related]
20. Superior Fidelity and Distinct Editing Outcomes of SaCas9 Compared with SpCas9 in Genome Editing.
Yang ZX; Fu YW; Zhao JJ; Zhang F; Li SA; Zhao M; Wen W; Zhang L; Cheng T; Zhang JP; Zhang XB
Genomics Proteomics Bioinformatics; 2023 Dec; 21(6):1206-1220. PubMed ID: 36549468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
